Urine test to guide early treatment in type 2 diabetes
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have type 2 diabetes but not severe heart failure (class IV).
- You can understand and sign a consent form.
- You do not have advanced kidney disease (e.g., needing dialysis or having a transplant).
- You are not pregnant or planning to become pregnant, and use effective birth control if needed.
- You have not had a heart attack or stroke in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called an SGLT2 inhibitor (canagliflozin-like) can help slow kidney disease in people with type 1 diabetes. It may help protect your kidneys if you already have protein in your urine and reduced kidney function.
This study tests a once-daily pill called finerenone to see if it can reduce protein in the urine (a sign of kidney damage) in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and slow down disease progression.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This study tests if dapagliflozin (a medication for diabetes and kidney health) can help prevent kidney injury in people with type 1 diabetes. It is for adults aged 18 to 64 who have moderately reduced kidney function and some protein in their urine.
Hear when a new Type 2 DM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.